Single-cell sequencing uncovers sensory neuron-mediated CGRP signaling as a driver of sarcoma progression
- PMID: 41118222
- PMCID: PMC12582254
- DOI: 10.1073/pnas.2500161122
Single-cell sequencing uncovers sensory neuron-mediated CGRP signaling as a driver of sarcoma progression
Abstract
Bone pain is a presenting feature of bone cancers such as osteosarcoma (OS), relayed by skeletal-innervating peripheral afferent neurons. Potential functions of tumor-associated sensory neurons in bone cancers beyond pain sensation are unknown. To uncover neural regulatory functions, a chemical-genetic approach in mice with a knock-in allele for TrkA was used to functionally perturb sensory nerve innervation during OS growth and disease progression. TrkA inhibition in transgenic mice led to significant reductions in sarcoma-associated sensory innervation and vascularization, skewed tumor associated macrophage polarization, reduced tumor growth and metastasis, and prolonged overall survival. Single-cell transcriptomics revealed that sarcoma denervation was associated with phenotypic alterations in both OS tumor cells and cells within the tumor microenvironment, and with reduced calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF) signaling. Multimodal and multiomics analyses of human OS bone samples further implicated peripheral innervation and neurotrophin signaling in OS tumor biology. Next and in two parallel approaches to inhibit nerve ingrowth, we repurposed FDA-approved bupivacaine liposomes and separately blocked CGRP signaling using FDA-approved Rimegepant. Both strategies led to significant reductions in sarcoma growth, vascularity, and sarcoma-induced hyperalgesia. In sum, TrkA-expressing peripheral neurons positively regulate key aspects of OS progression and sensory neural inhibition disrupts CGRP signaling within the sarcoma microenvironment leading to significantly reduced tumor growth and improved survival. These data suggest that interventions to prevent pathological innervation of OS represent an adjunctive therapy to improve clinical outcomes and survival.
Keywords: neuropathic pain; sarcoma; skeletal innervation; tropomyosin receptor kinase A; vascularity.
Conflict of interest statement
Competing interests statement:A.W.J. is a paid consultant for Novadip and Lifesprout LLC. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict-of-interest policies. Y.G. is a principal investigator in a research grant from Medtronic, Inc. Y.G. received a research award from BioTissue, Inc.
References
MeSH terms
Substances
Grants and funding
- P01 AG066603/AG/NIA NIH HHS/United States
- R01 AR079171/AR/NIAMS NIH HHS/United States
- R21 AR078919/AR/NIAMS NIH HHS/United States
- R01 DE031488/DE/NIDCR NIH HHS/United States
- R01 DE031028/DE/NIDCR NIH HHS/United States
- 22-26743/Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)
- DBG-23-1155131-01-IBCD/American Cancer Society (ACS)
- 2021-MSCRFD-5641/Maryland Stem Cell Research Fund (MSCRF)
- HT9425-24-1-0051/DOD | USA | MRDC | U.S. Army Medical Research Acquisition Activity (USAMRAA)
- NS110598/HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- NS117761/HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- U19 NS130608/NS/NINDS NIH HHS/United States
- R01 NS 111929/Foundation for the NIH (FNIH)
LinkOut - more resources
Full Text Sources
Medical
Research Materials
